Table 1.
Baseline and Treatment Characteristics of the Total Study Population (N = 932)
| Characteristic | No. of Patients | % |
|---|---|---|
| Age, years | ||
| Median | 60 | |
| Range | 19-87 | |
| Sex | ||
| Male | 500 | 53.6 |
| Female | 432 | 46.4 |
| Race/ethnicity | ||
| White | 791 | 84.9 |
| Asian | 62 | 6.7 |
| African American | 60 | 6.4 |
| Other/unknown | 19 | 2.0 |
| Thrombosis risk factors | ||
| Hypertension | 295 | 31.7 |
| Coronary artery disease | 62 | 6.7 |
| Atrial fibrillation/arrhythmias | 26 | 2.8 |
| Prior strokes | 4 | 0.4 |
| Central venous catheter | 266 | 28.5 |
| Surgery within 2 months | 169 | 18.1 |
| ESA 6 weeks before/4 weeks after | 167 | 17.9 |
| Karnofsky performance status, % | ||
| Median | 80 | |
| IQR | 80-90 | |
| Obesity (BMI ≥ 30 kg/m2) | 157 | 16.8 |
| Diabetes | 99 | 10.6 |
| Previous TEE | 90 | 9.7 |
| IVC filter | 11 | 1.2 |
| Khorana variables | ||
| Site of cancer | ||
| Very high risk | 193 | 21.7 |
| High risk | 319 | 34.2 |
| Prechemotherapy platelet count ≥ 350,000/μL | 230 | 24.7 |
| Prechemotherapy leukocyte count > 11,000/μL | 156 | 16.7 |
| Prechemotherapy hemoglobin < 10 g/dL or use of ESA | 214 | 23.0 |
| BMI ≥ 35 kg/m2 | 35 | 3.8 |
| Khorana risk score | ||
| 0 | 224 | 24.0 |
| 1 | 293 | 31.4 |
| 2 | 245 | 26.3 |
| 3 | 129 | 13.8 |
| 4 | 35 | 3.8 |
| 5 | 6 | 0.6 |
| Khorana risk group | ||
| Low | 224 | 24.0 |
| Intermediate | 538 | 57.7 |
| High | 170 | 18.2 |
| Cancer diagnosis | ||
| Lung | 204 | 21.9 |
| Gastric/GE junction | 114 | 12.2 |
| Head and neck | 94 | 10.1 |
| Pancreatic | 79 | 8.5 |
| Melanoma | 69 | 7.4 |
| Ovarian | 57 | 6.1 |
| Esophageal | 46 | 4.9 |
| Germ cell | 39 | 4.2 |
| Cervical/uterine/vulvar | 39 | 4.2 |
| Bladder | 33 | 3.5 |
| Endometrial | 22 | 2.4 |
| Cholangiocarcinoma | 18 | 1.9 |
| Mesothelioma | 15 | 1.6 |
| Colorectal/anal/small bowel | 13 | 1.4 |
| Other | 90 | 9.7 |
| Stage of disease | ||
| Early | 66 | 7.1 |
| Locally advanced | 415 | 44.5 |
| Metastatic | 426 | 45.7 |
| Undocumented | 19 | 2 |
| Other | 6 | 0.6 |
| Chemotherapy regimens | ||
| Cisplatin + gemcitabine | 134 | 14.4 |
| Cisplatin + radiation | 94 | 10.1 |
| Cisplatin + irinotecan | 89 | 9.6 |
| Cisplatin + etoposide | 80 | 8.6 |
| Cisplatin + vinblastine + temozolomide | 57 | 6.1 |
| Cisplatin + pemetrexed | 43 | 4.6 |
| Cisplatin IP + paclitaxel IV/IP | 33 | 3.5 |
| Cisplatin + pemetrexed + bevacizumab | 33 | 3.5 |
| Other cisplatin-based regimens | 369 | 39.6 |
| Mean cisplatin dose, mg/m2 | ||
| Median | 40 | |
| IQR | 25-65 | |
| Cumulative cisplatin dose, mg/m2 | ||
| Median | 200 | |
| IQR | 120-300 | |
| No. of cisplatin doses | ||
| Median | 5 | |
| IQR | 3-7 | |
| Entire time on cisplatin, days | ||
| Median | 61 | |
| IQR | 28-91 | |
Abbreviations: BMI, body mass index; ESA, erythropoiesis-stimulating agent; GE, gastroesophageal; IP, intraperitoneal; IQR, interquartile range; IV, intravenous; IVC, inferior vena cava; TEE, thromboembolic event.